| Business Summary | | Sangamo
Biosciences,
Inc.
is
engaged
in
the
development
of
novel
transcription
factors
for
the
regulation
of
gene
expression.
Transcription
factors
are
proteins
that
turn
genes
on
or
off
by
recognizing
specific
deoxyribonucleic
acid
(DNA)
sequences.
The
Company's
Universal
Gene
Recognition
platform
is
a
proprietary
technology
based
on
engineering
a
naturally
occurring
class
of
transcription
factors
known
as
zinc
finger
DNA-binding
proteins
(ZFPs).
By
engineering
ZFPs
so
that
they
can
selectively
bind
to
and
regulate
a
target
gene,
the
Company
has
created
ZFP
transcription
factors
that
can
control
gene
expression
and,
consequently,
cell
function.
The
Company
intends
to
establish
Universal
Gene
Recognition
as
a
broadly
used
technology
platform
for
commercial
applications
in
pharmaceutical
discovery,
human
therapeutics,
DNA
diagnostics
and
agricultural
and
industrial
biotechnology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Sangamo
Biosciences,
Inc.
is
engaged
in
the
research
and
development
of
novel
transcription
factors
for
the
regulation
of
gene
expression.
For
the
six
months
ended
6/30/01,
total
revenues
increased
28%
to
$2
million.
Net
loss
applicable
to
Common
fell
25%
to
$4.5
million.
Revenues
reflect
the
new
Universal
Genetools
agreement
income.
Lower
loss
was
partially
offset
by
$1.5
million
preferred
dividend
and
higher
research
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Edward Lanphier II, 44 Pres,
CEO, Director | $448K | -- | Peter Bluford, 46 VP,
Corp. Devel. | 186K | $750K | Casey Case, Ph.D., 45 VP,
Research | 191K | 32K | Shawn Johnson, 33 Director
of Fin. | -- | -- | Eric Rhodes, 40 Director
of Commercial Devel. | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|